Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France: tough new pricing guidance with HTA focus

This article was originally published in Clinica

Executive Summary

The French government has issued guidance to its healthcare products pricing committee (CEPS), requiring that its pricing negotiations take into account the results of medico-economic evaluations – ie health technology assessments (HTAs).

You may also be interested in...



Medtech sales over €20m? New French rule says medico-economic evaluation needed

Catherine Defabianis explains strict new rules for determining whether innovative medical devices should be reimbursed

France: €20 million turnover to trigger medico-economic evaluation

Catherine Defabianis explains strict new rules for determining whether innovative drugs and medical devices should be reimbursed.

The extremes to which the French are going for ultra high-risk innovative products

Just how far do the French authorities feel it is necessary to go to demonstrate the safety of products considered to be higher risk than all others? Catherine Defabianis, director of information and regulatory intelligence at A.R.C. Pharma (France) , gives details here of the new measures that the French national agency for healthcare product safety ANSM put forward to the country's parliament in late October for those ultra high-risk medical devices

Topics

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel